| *Sponsored
With Breaking News, Low Float (Nasdaq: CVKD) May Start Earning Buzz Early Thursday
June 12th Dear Reader,
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) just dropped breaking news!
Check it out:
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke
Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39k per event
Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population
PONTE VEDRA, Fla., June 12, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.
...
"Despite decades of use, warfarin has significant limitations – especially in complex patients with LVADs," said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. "This research reinforces our conviction that tecarfarin has the potential to transform anticoagulation management for this high-risk population who currently has no alternative options."
Read the full article here.
Mix this news with a low float of fewer than 2Mn shares and a pair of analyst targets (below) suggesting strong upside potential, and it's probably no surprise why this Biopharma idea tops my watchlist today.
Take a moment to review my initial report below and consider (Nasdaq: CVKD) for your radar. -----
Imagine a world where patients with advanced heart failure and rare cardiovascular conditions finally have a safer, more effective option for chronic blood clot prevention.
A late-stage biopharmaceutical company, recently recognized with FDA orphan drug designations, is advancing a novel oral anticoagulant—engineered to overcome the limitations of traditional therapies by sidestepping common drug interactions and kidney-related complications.
With pivotal clinical trials on the horizon and strong partnerships with leading device manufacturers, this organization is poised to transform care for underserved populations.
The future of cardiovascular medicine is shifting, and this team is at the center of that change.
Now, mix in a low float of fewer than 2Mn shares and a pair of analyst targets suggesting SIGNIFICANT upside potential, and there's no doubt why this Nasdaq profile just rocketed up my watchlist.
Drop what you're doing and consider this under-the-radar idea for your radar:
*Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)*
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease.
Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy.
Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.
And based on several potential breakout catalysts, (Nasdaq: CVKD) has found its way to the top of my watchlist. Check them out:
#1. A Low Float Could Create An Environment Of Heightened Volatility Potential.
#2. A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.
#3. Another Analyst Reiterates A $30 Target For CVKD.
#4. A Key Collaboration Agreement Strengthens Access To Clinical Trial Sites.
#5. Manufacturing And Supply Chain Milestones For Tecafarin Mark Important Progress.
But more on those in a second...
Company Breakdown: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an investigational anticoagulant designed as a superior and safer Vitamin K antagonist (VKA) for patients with implanted cardiac devices or rare cardiovascular conditions.
The company strives to improve patient outcomes and reduce major adverse events among these populations, who currently lack any approved chronic anticoagulation options besides warfarin—a medication known for its serious side effects and complex management requirements.
Through its innovative approach, Cadrenal aims to alleviate some of the most significant challenges faced by patients and healthcare providers who rely on warfarin.
Cadrenal’s Phase 3-ready drug candidate, tecarfarin, represents a novel VKA anticoagulant supported by extensive data suggesting its potential to be superior to warfarin, with the possibility of fewer adverse events such as strokes, heart attacks, bleeding, and death.
Tecarfarin has received orphan drug designation for heart failure patients with left ventricular assist devices (LVADs), as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib).
The company is actively pursuing pivotal clinical trials and exploring clinical and commercial partnership opp's.
Cadrenal also plans to investigate tecarfarin in patients with mechanical heart valves who experience anticoagulation difficulties due to genetic warfarin resistance, polypharmacy, or kidney impairment.
Tecarfarin is metabolized through a different pathway than warfarin, and data indicate that its efficacy remains unaffected by common drug-drug interactions or kidney impairment—challenges that are prevalent among these patient populations.
Phase 2/3 clinical trials have demonstrated that tecarfarin may offer greater stability and increased time in therapeutic range, which is inversely correlated with major adverse events.
As the only new VKA blood thinner in development specifically for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo, seeking to innovate a new anticoagulant that delivers better care to underserved patients.
Tecarfarin’s Metabolic Advantage
Tecarfarin is metabolized via an alternate pathway that is abundant and essentially insaturable, thereby avoiding the bottleneck in the CYP450 pathway where warfarin is metabolized. | 
Tidak ada komentar:
Posting Komentar